Hermes Biosciences is a life-science tools startup focused on turning extracellular vesicles (EVs) into a practical and standardized resource for precision medicine. Its flagship product is a benchtop, fully automated instrument designed to isolate EVs at higher yield and purity than existing approaches, enabling more reliable downstream analysis for clinical researchers in academia, biopharma, and diagnostic laboratories. The company intends to launch its first commercial instrument in 2026, offering a scalable and hands-off workflow that can be integrated into regulated clinical environments. By improving EV capture, Hermes aims to advance biomarker discovery, non-invasive diagnostics, and targeted therapeutics. The San Francisco-based team is still pre-revenue, using newly secured capital to complete product development, expand manufacturing capabilities, and build out sales channels. The firm’s initial $6 million seed financing may grow as additional investors are engaged, giving Hermes runway to reach its commercialization milestones.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025